Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to learn about clinical and functional outcomes in patients with Chronic rhinosinusitis with nasal polyps and comorbid Severe Eosinophilic Asthma and patients with Chronic rhinosinusitis with nasal polyps only treated with mepolizumab compared to healthy controls. Participants will be asked to give nasal, blood and sputum samples before mepolizumab administration (T0) and at 3 (T3), 6 (T6) and 12 (T12) months after mepolizumab initiation The main aims are to identify airways microbiota modifications and differential gene expression after mepolizumab initiation. Researchers will compare: Patients with Chronic rhinosinusitis with nasal polyps and comorbid Severe Eosinophilic Asthma Patients with Chronic rhinosinusitis with nasal polyps only Healthy subjects The research will address the following questions: What are the prospective clinical and functional outcomes of mepolizumab treatment What is the impact of mepolizumab therapy on the airways microbiota and how this may relate to a potentially reduced need for steroids What are the host differential gene expression patterns and the immune/inflammatory (cytokines/chemokines) profile alterations in airways microenvironment and in systemic circulation in response to therapy What are the associations between host and microbiome variables for building up diagnostic and predictive biomarker classifiers of responsive disease endotypes

Detailed Description
-----------------
Chronic rhinosinusitis (CRS) has been divided into two subtypes: CRS with (CRSwNP) and without nasal polyps (CRSsNP), which not only differ in terms of presence of polyps, but also appear to have distinct pathogenesis and clinical presentations. It is known that CRSwNP patients have a greater disease burden compared with those suffering from CRSsNP with respect to disease severity and poor treatment. More specifically, approximately 85% of CRSwNP patients are characterized by severe symptoms, recurrent disease and a dominant Th2 endotype associated with a marked infiltration of eosinophils and mast cells, goblet hyperplasia and increased levels of Th2 inflammatory cytokines including Interleukin IL-4, IL-5, and IL-13. An additional hallmark of CRSwNP is the loss of healthy barrier function in sinonasal epithelial cells, increased permeability, decreased epithelial resistance, and a high degree of tissue remodeling compared with cells from CRSsNP patients and control individuals. This loss of barrier function is reflective of a general inflammatory process, though it is unclear if the epithelial cells are inherently abnormal or if the state is induced. Treatment for CRS is most frequently glucocorticoid-based, but response is quite variable in patients with nasal polyps and side-effects from oral steroids limit their long-term efficacy. An inverse relationship between glucocorticoid receptor β expression in nasal polyp tissue and steroid efficacy has been observed. Furthermore, neutrophil accumulation in nasal polyp tissue has been related to corticosteroid insensitivity. Some individuals exhibit a very high level of resistance to steroid therapy thus underscoring the need for therapeutics targeting non-steroid-responsive pathophysiologic mechanisms involved in sinus polyp formation. Asthma is frequently a comorbid condition sharing similar pathophysiology in CRSwNP patients, which affects 20-60% of diseased individuals. Yet, specific subsets of patients such as those with IL-5-enriched nasal polyps are characterized by a greater percentage of asthma and revision surgery. Clinically, CRSwNP with comorbid asthma (CRSwNP + AS) is associated with even more severe sinonasal symptoms and worse quality of life, and it is more difficult to treat both medically and surgically. Correspondingly, asthma in the presence of nasal polyposis is harder to control, being more exacerbation prone, with increased airway obstruction and more extensive eosinophilic inflammation. Although a clear correlation apparently exists between sinonasal and lower airway inflammation in patients with CRSwNP+AS, the definitive underlying mechanism(s) remains poorly elucidated. The airways microbiota, i.e. the niche-specific communities of microbes including bacteria, fungi, archaea and viruses that inhabit the respiratory tract, has been proved to play a critical role in airway health and immune cells homeostasis -including eosinophils regulation- through its constant interaction with the mucosal immune system. Alterations in the composition and diversity of microbiome across the respiratory tract may contribute to the observed inflammatory crosstalk in CRSwNP + AS, and perhaps influence patients' response to treatment. Nasal and lower airway microbiota dysbiosis have been proved to be implicated in the persistence of characteristic inflammatory endotypes in both CRSwNP and asthma. It has been shown that bacterial dysbiosis is correlated with CRS status and that specific microbiota taxonomic classifications are correlated with patient phenotypes, including the presence of nasal polyps. A high proportion of patients with CRSwNP are colonized with Staphylococcus (S.) aureus and IgE antibodies to S. aureus enterotoxins are frequently found in diseased tissue specimens. Both S. aureus and Pseudomonas aeruginosa bacteria can disrupt the epithelial barrier contributing to presumed physiologic mechanisms for CRSwNP development. It has been previously demonstrated that S. aureus is able to drive Th2 type inflammation in CRSwNPand that the expression of IL-5 and of IgE against S. aureus superantigens (SE-IgE) within polyp tissue is associated with comorbid asthma and CRSwNP recurrence. Furthermore, antimicrobial compounds including lysozyme, S100 proteins, and β-defensins all are decreased in CRSwNP patients compared to matched controls. This reduction in natural defenses could play a key role in shifting the balance towards dysbiosis. Furthermore, in addition to bacterial microbiome which has been the focus of most recent studies, the contribution of fungal microbiota to allergic airway diseases has been recently emerged. An alternative proposed pathogenic mechanism for Th2-biased CRS is that T-cells are allergically sensitized to fungi in the ambient environment, leading to allergic inflammation characterized by a Th2-high state. Overall, a distinct microbiome role in CRSwNP and asthma pathogenesis is actually recognized. However, the significance of interactions between the lower/upper airways flora and the host local and systemic inflammatory response has not yet been well defined neither such a knowledge is exploited for a more accurate patients classification and selection of best possible therapeutic manipulation to change disease progression. Evidently, an optimal diagnostic approach for CRSwNP + AS would include use of very specific biomarkers ensuring a detailed endotyping, whereas, there is a growing consensus that both diseases should be treated to improve therapeutic outcome. However, the management of CRSwNP + AS patients who remain uncontrolled despite medical and often surgical intervention poses a great challenge to clinicians. Fortunately, there has been significant innovation and expansion in the treatment armamentarium since the advent of biological therapies. Targeted biologics (monoclonal antibodies against IL-4, IL-5, IL-13 and IgE) for treating asthma are now being used for CRSwNP with encouraging results. Recently, mepolizumab (Nucala; GlaxoSmithKline), an anti-IL5 humanized mab known to efficiently down-regulate the eosinophilic inflammatory pathway and to exhibit clinical benefit in patients with severe, eosinophilic asthma, has completed a phase 3 trial (SYNAPSE; NCT03085797) including 413 subjects with CRSwNP. Early results showed treatment with mepolizumab had a significant difference in median nasal polyp score compared to baseline (-0.73; 95% CI: -1.11 to -0.34) and nasal obstruction visual analog score compared to baseline (-3.14; 95% CI: -4.09 to -2.18; unpublished data). However, there are only limited longitudinal studies evaluating this biologic's efficacy in CRSwNP+AS patients, while the assessment of action mode and biomarkers predicting responsiveness, remain to be elucidated. Despite the persuasive rationale for systemic targeting of shared pathways in CRSwNP+AS with novel biologics, in clinical practice the nose and lungs are often treated as separate entities and these therapeutics are considered rather challenging for the clinicians due to their high cost and necessity for careful selection of patients and right treatment. Furthermore therapeutic decision-making is still based on a rather trial-and-error approach, resulting in treatment failures or relapses. There is clearly a need for a personalized medicine approach that would allow for a more accurate prediction of the appropriate choice of the drug at the initial assessment, and ideally would communicate chances of long-term success to an individual patient. The principal goal of this three arms RWE study (CRSwNP+AS, CRSwNP-AS, healthy controls) study is to develop signatures of host-microbiome biomarkers of both diagnostic and predicting value in order to provide a rational guideline for mepolizumab selection in precision treatment of patients with CRSwNP+AS. In this frame, mepolizumab therapeutic potential will be assessed in relation to the rather heterogeneous presentations of Th2 inflammation and airways microbiome structure. The protocol will take on the question of microbiome dysbiosis involvement in immune activation and dysfunction contributing to CRSwNP + AS diversity and delving into the complex patterns of host-microbiota molecular interactions in the upper and lower airways that may shape patients' clinical predisposition to mepolizumab therapy. To address the study objectives a longitudinal design is proposed combining clinical assessments with high-throughput multi-omics analyses of patients' samples and advanced bioinformatics for data integration. The starting point of the project will be the consent recruitment of healthy controls, CRSwNP + AS and CRSwNP - AS participants. Collection of biological samples from patients and clinical assessment/measurements of cell counts will take place at baseline, i.e. the day of treatment initiation before mepolizumab administration (T0) and at 3 (T3), 6 (T6) and 12 (T12) months after mepolizumab initiation. Samples from healthy participants will be collected only at baseline (T0) and analyzed in parallel with the corresponding samples from CRSwNP patients. DNA and RNA will be isolated from induced sputum and nasal samples collected at T0 and T3 for subsequent 16S rRNA gene amplicon sequencing, DNA shot-gun sequencing (applied only in selected number of patients and healthy controls) and bulk RNA sequencing (RNAseq), to identify airways microbiota modifications and differential gene expression, respectively. Peripheral blood mononuclear cells (PBMC) from a representative number of patients and healthy controls will be also analyzed at the same time points by single-cell RNA sequencing (scRNAseq). In parallel, the dynamic pattern of cytokines/chemokines in serum/airways samples will be determined by xMAP immunoassays at T0 and T3. Subsequently, multiple comparisons at the level of microbiome and host parameters will be undertaken mainly through two paths. First, between patients and healthy controls at T0 to assess differences of disease versus normal condition; Second, pairwise in each patient at T0 and at time intervals, mostly at T3, after treatment intervention, to capture potential alterations in response to mepolizumab. Next, a thorough integrative analysis engaging clinical data and multi-omics data (from microbiome, bulk RNAseq, scRNAseq as well as cytokinome/chemokinome analyses) will be undertaken to investigate possible microbiome-host interactions. Finally, this integrative analysis will be exploited to gain a global view of hub genes, inflammatory mediators and microbial taxa involved in key interactions and to build biomarker signatures that might serve as indicators of specific disease subtypes and/or predictors of mepolizumab treatment outcome.

Official Title
-----------------
Evaluation of Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis With Nasal Polyps and Comorbid Severe Eosinophilic Asthma: an Integrative Multi-omics Approach to Assess Biomarker Signatures of Responsive Disease Endotypes

Conditions
-----------------
Chronic Rhinosinusitis With Nasal Polyps, Severe Eosinophilic Asthma, Chronic Rhinosinusitis Without Nasal Polyps

Intervention / Treatment
-----------------
* Drug: Mepolizumab 100 MG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Eligible for inclusion will be patients diagnosed with CRSwNP according to the European Position Paper on Rhinosinusitis and Nasal Polyps that fulfill the criteria for initiating treatment with biologics as standard of care [49], suffering or not from comorbid severe asthma (CRSwNP + AS, CRSwNP - AS, respectively) who will consent to participate in the study. The study will not influence prescribing of mepolizumab to patients. Eligible to treatment women in childbearing potential will be informed before consent that they must take care of contraception and potential pregnancy during therapy as there is not enough data regarding the use of mepolizumab during pregnancy. All patients with severe asthma will be qualified for treatment with mepolizumab in accordance with GINA guidelines. Exclusion Criteria: Patients less than 18 years of age, subjects suffering from COPD, known or suspected immunodeficiency or autoimmune disease, chronic interstitial lung diseases, cystic fibrosis, individuals exposed to systemic corticosteroid/immunosuppressive treatments, biologics for asthma care or antibiotics within the previous 3 months before mepolizumab administration, active smokers and obese individuals will be excluded from this study. Pregnant women will not be included into the study because of the potential changes that their microbiome and other host parameters could undergo during pregnancy. The control group will comprise healthy volunteers who will be free from CRS, asthma, and atopy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy control subjects<br>Healthy control subjects withouth asthma nor chronic rhinosinusitis or other chronic respiratory diseases | |
| Chronic rhinosinusitis with nasal polyps (CRSwNP) patients with comorbid severe asthma<br>Patients that have chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbid severe asthma will be enrolled | Drug: Mepolizumab 100 MG<br>* Monthly administartion of mepolizumab 100mg<br>* Other names: nucala;|
| Chronic rhinosinusitis with nasal polyps (CRSwNP) patients without asthma<br>Patients that have chronic rhinosinusitis with nasal polyps (CRSwNP) without asthma will be enrolled | Drug: Mepolizumab 100 MG<br>* Monthly administartion of mepolizumab 100mg<br>* Other names: nucala;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean change from baseline in Sino-nasal outcome test-22 (SNOT-22) score | SNOT-22 score will be considered as a measure of post-treatment alterations in CRSwNP clinical symptoms | at baseline and in 3, 6 and 12 months | 
| Asthma control test (ACT) | ACT will assess potential treatment-induced alterations in asthma symptoms | at baseline and in 3, 6 and 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean change of nasal endoscopic polyps score | Nasal endoscopic polyps score will be considered as a measure of post-treatment alterations in CRSwNP participants | at baseline and in 3, 6 and 12 months | 
| Mean change of the polyposis severity visual analog scale (VAS) score | Polyposis severity VAS score will estimate potential post-treatment changes in CRSwNP participants | at baseline and in 3, 6 and 12 months | 
| Forced Expiratory Volume at 1 s % (%FEV1: FEV1/FEV1 predicted) and Morning Peak Expiratory Flow measurements | FEV1: FEV1/FEV1 predicted and Morning Peak Expiratory Flow measurements will assess potential treatment-induced alterations in pulmonary function | at baseline and in 3, 6 and 12 months | 
| Fractional Exhaled Nitric Oxide Testing (FENO) | FENO measurements will assess potential treatment-induced alterations in airways inflamation | at baseline and in 3, 6 and 12 months | 
| Forced oscillation technique (FOT) measurements at baseline and after 3, 6 and 12 months of mepolizumab treatment | FOT measurements will estimate post-treatment changes in respiratory mechanics | at baseline and in 3, 6 and 12 months | 
| Hospital Anxiety and Depression Scale (HADS) questionnaire | HADS questionnaire will track evolution of psychological symptoms in response to treatment | at baseline and in 3, 6 and 12 months | 
| Mean change from baseline in Asthma Quality of Life Questionnaire (AQLQ) | AQLQA will assess changes in asthma-specific health-related quality of life in response to mepolizumab therapy | at baseline and in 3, 6 and 12 months | 
| Mean change from baseline in immune cells (eosinophil/neutrophil) counts in nasal, sputum and blood samples | Immune cells measurements will indicate the potential alterations in airway (nasal, sputum) and systemic (blood) inflammation in response to mepolizumab treatment | at baseline and in 3, 6 and 12 months | 
| Mean change from baseline of cytokines/chemokines levels in blood and airways samples | Multiplex measurements of cytokines/chemokines levels will inform for treatment-induced alterations in airway (nasal, sputum) and systemic (blood) inflammation | at baseline and in 3 months | 
| Differential gene expression (fold changes) in nasal and sputum samples | Differential gene expression will evaluate the treatment-mediated alterations in the airway transcriptome | at baseline and in 3 months | 
| Differential single-cell gene expression (fold changes) of Peripheral Blood Mononuclear Cells (PBMC) from responders and non-responders to mepolizumab treatment | Differential single-cell gene expression analysis will estimate the potential treatment-induced changes in single-cell gene expression in responders versus non-responders to mepolizumab treatment | at baseline and in 3 months | 
| Mean change from baseline in airway (sputum, nasal) microbiome alpha and beta diversity indices at 3 months post-treatment in airway samples | Measurement of the alpha and beta microbiome diversity indices will assess the treatment-induced alterations in the microbiome characteristics | at baseline and in 3 months | 
| Differential abundances of microbial taxa (fold changes) from baseline at 3 months post-treatment in nasal and sputum samples | Differential taxa abundance will evaluate the treatment-mediated alterations in the abundance of specific airway microbial taxa | at baseline and in 3 months | 
| Differential abundances of predicted metabolic pathways (fold changes) from baseline at 3 months post-treatment in nasal and sputum microbiome | Differential abundance of metabolic pathways will estimate the treatment-mediated alterations in the microbiome function | at baseline and in 3 months | 
| Predictive biomarker classifiers of responsive disease endotypes | Harness associations between host and microbiome variables for building up diagnostic and predictive biomarker classifiers of responsive disease endotypes | two years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic Rhinosinusitis, Severe Eosinophilic Asthma, Microbiome, Nasal Polyps, Mepolizumab